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1.1 Thymus: The site of T cell development 
For an effective immune response, antigens from disease-causing agents such 
as bacteria and viruses are recognized by the adaptive immune system. Two 
major components of this arm of the immune response are B and T cells, both of 
which have antigen receptors that respond to a vast range of antigens. These 
lymphocyte populations, however, develop in different tissues: for T cells, the 
primary lymphoid organ is the thymus. Like B cells, T cells develop from 
hematopoietic stem cells (HSC) in the bone marrow, and during fetal life, in the 
liver. Lymphoid progenitors access circulation and migrate into the thymus. 
There, these cells, called thymocytes, undergo differentiation and selection steps 
through their interactions with thymic antigen presenting cells. This process 
generates a mature repertoire of T cells that is functional – able to protect the 
organism from pathogens it may encounter, but also self-tolerant. 
 
In all species with T cells, development occurs in the thymus. If the thymus is 
surgically removed (thymectomized) early in life or if patients are born with 
mutations that impact the development of the thymus, there is striking 
immunodeficiency, leading to increased susceptibility to infection1. Anatomically, 
this organ is located behind the sternum, and its distinct lobes are divided into 
the outer cortex and inner medulla2. The thymus is primarily composed of 
developing thymocytes, but thymic stromal cells and hematopoietic antigen 
presenting cells are present as well, and create unique microenvironments in 
these distinct regions. This compartmentalization of thymocytes provides for 
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distinct cues that are needed to support T cell development through the different 
developmental stages.  
 
Initially, thymic precursors enter into the thymic parenchyma near the cortico-
medullary junction (CMJ)2. As they develop, immature thymocytes migrate into 
and through the densely packed cortex, where they are guided by cues from 
surrounding cells. These cells include large, branched cortical epithelial cells 
(cTEC), dendritic cells (DC), and macrophages. Here, thymocytes are committed 
to the T cell lineage and progress through sequential differentiation steps. The 
thymic environment provides chemokines that later guide the thymocytes to 
leave the cortex into the thymic medulla. The thymic medulla has distinct thymic 
epithelial cells, aptly named medullary thymic epithelial cells (mTEC), as well as 
other antigen presenting cells. More mature thymocytes reside in the medullary 
region: ab T cells become MHC class I or MHC class II restricted, and become 
CD8+ or CD4+ thymocytes. These surviving thymocytes then emigrate from the 
thymus into the periphery as mature T cells.  
 
Thymic stromal cells, including cTEC and mTEC, form the supporting meshwork 
needed for thymic structure and proper thymocyte development3. Foxn1 is a 
transcription factor essential for TEC development, and Foxn1 deficiency leads to 
a thymic rudiment that cannot sustain lymphopoiesis. Notably, defects in Foxn1 
have been described in both mice and humans, with a phenotype that includes 
hair loss and T cell immunodeficiency4. In humans, this disorder is referred to as 
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the Pignata Guarino syndrome, and in mice, the nude mutation. Nude mice 
particularly shed light on the specific need for thymic stromal cells for T cell 
development: when bone marrow from nude mice is transplanted into mice with 
normal stromal cells, functional T cells develop, but they do not when bone 
marrow from normal mice is transplanted in mice with the nude mutation. Another 
human disease with a similar phenotype of athymia and T cell deficiency is 
DiGeorge syndrome, but these patients have deletions in chromosome 22q11, 
which encodes Tbx1. Taken together, these observations show that the thymus 
is the major site of T cell maturation and is necessary for functional peripheral T 
cells. 
 
1.2 Positive and negative selection 
Conventional ab T cells in the periphery are either CD4+ helper or CD8+ cytotoxic 
T cells, and this divergence of co-receptor expression and effector cell type is 
determined in the thymus. In the thymus, this decision is made after surface TCR 
expression: only positively selected double positive (DP) thymocytes can 
transition into CD4 or CD8 single positive (SP) thymocytes. The rearrangement 
and pairing of ab TCR genes is random, and the TCRs on DP thymocytes have 
specificities that react to a wide range of antigens (both self or foreign) or don’t 
react at all. Additionally, some receptors, while potentially capable of binding to a 
peptide antigen, may not bind to the peptide when presented by that individual’s 
MHC molecules. For any individual, a useful T cell is one that can recognize an 
antigen (such as a foreign antigen from a pathogen) presented by a self MHC 
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molecule. Thus, a positive selection step is needed to enrich the T cell repertoire 
“with MHC restricted” TCRs specific for antigens only in the context of the host’s 
limited MHC molecules5. Additionally, TCRs that bind strongly to self-peptides 
present a risk, as these T cells may trigger autoimmunity. Therefore, a negative 
selection step is also required to prune autoreactive clones from the T cell 
repertoire. The result of these selection checkpoints is mature T cells that are 
MHC restricted and self-tolerant, and can be exported from the thymus into the 
periphery.  
 
1.2.1 Positive selection generates a “MHC-restricted” T cell pool 
In the thymic cortex, DP thymocytes audition for selection5. These immature cells 
only have a life-span of 3 to 4 days, and without engagement of the TCR, their 
default pathway is one of apoptosis – a form of programmed cell death called 
‘death by neglect’. It is estimated at anywhere between 85 to over 90% of these 
precursors are unable to be selected and are eliminated in this manner5, 6. Cells 
that avoid this fate undergo positive selection, in which the ab TCR binds with 
low to intermediate avidity to self-peptide:MHC complexes presented by cTEC, 
promoting cell survival. As the self-peptides presented in the thymus are 
displayed on the host’s own MHC molecules, positive selection ensures that only 
self-MHC restricted DP thymocytes mature into CD4+ or CD8+ SP thymocytes. 
After undergoing positive selection in the cortex, DP thymocytes upregulate 
chemokine receptors such as CCR7 and migrate towards the medulla2. As the 
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thymocyte crawls through the cortico-medullary junction into the medullary 
region, it interacts with other thymic APC, which can drive negative selection. 
 
1.2.2 Negative selection generates a “self-tolerant” T cell pool 
Among the TCR expressed by DP thymocytes, some bind strongly to self-
peptide:MHC. During the selection processes in the thymus, these autoreactive T 
cell clones are removed from the repertoire in a process called negative 
selection5. Apoptosis by these cells ‘deletes’ them from the T cell repertoire, and 
elimination of autoreactive TCRs via cell death is also known as clonal deletion. 
While the majority of negative selection occurs in cortex at the DP stage, there is 
also a second wave of medullary clonal deletion in more mature thymocytes 5, 7. 
The deletion of self-reactive T cells clones is key in establishing central 
tolerance, but along with clonal deletion, there is an additional tolerance 
mechanism: the development of regulatory T cells (Treg). Regulatory T cells are 
self-reactive CD4+ T cells that express CD25 and the transcription factor FOXP3. 
They generally suppress immune responses, as opposed to initiating them. While 
they are only a small proportion of both developing CD4 SP thymocytes (~1%) 
and CD4+ T cells in secondary lymphoid organs (~10-15%), they play a key role 
on immune homeostasis8. This clonal deletion and Treg selection can be 
mediated by mTEC as well as hematopoietic APC such as dendritic cells and B 
cells9.  
 
1.2.3 Role of peptide:MHC in negative and positive selection 
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The model that for positive and negative selection, the signal strength of the 
interaction between the self-peptide:MHC and TCR differ is known as the affinity 
model of selection5. On one end, receptors that do not bind and respond to self-
peptide:MHC will automatically undergo cell death after a few days — called 
neglect; while on the other, receptors that bind with high affinity and respond 
strongly undergo cell death by clonal deletion. In the middle is a window of 
positively selected conventional T cells with receptors that bind with weaker 
affinity to self-peptide:MHC. While thymocytes that have high affinity interactions 
with self-peptides undergo generally apoptosis and are deleted, some cell types, 
such as regulatory T cells and other specialized lymphocytes are more self-
reactive but are able to avoid this cell fate. These agonist selected cells require 
other molecular factors, such as CD1d and costimulatory molecules for their 
selection, but there is some stochastic overlap between agonist selected cells 
and clonal deletion10. 
 
1.3 Thymic antigen presenting cells 
The different antigen presenting cells in the cortex and medulla of the thymus are 
specialized for positive and negative selection5. cTEC are essential for positive 
selection. The crucial role that cTEC have in selection is mediated in part by their 
peptide processing machinery, which gives them the ability to present a largely 
unique peptide:MHC repertoire (also known as the peptidome)5, 9. In APC, 
peptide fragments are loaded onto MHC molecules after cytosolic proteins are 
degraded by proteasomes. These proteasomes have a catalytic core that 
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consists of three subunits: b1, b2, and b5. cTEC have the unique proteasome 
subunit b5t, while other APC can only express b5 or b5i. This endows cTEC with 
the ability to present specialized peptides produced by the thymoproteosome 
(specifically composed of subunits b1i, b2i, and b5t), allowing for a peptide:MHC 
peptidome that promotes positive selection and shapes the T cell repertoire.  
The thymic cortex is also home to hematopoietic APC which play a role in 
selection. Notably, these bone marrow derived APC, such as dendritic cells, can 
mediate clonal deletion, and in fact, contribute to approximately half of clonal 
deletion events7. SIRPa+ DC (also known as cDC2)  are found within the thymic 
cortex but are migratory – capable of picking up antigen from the periphery 
before homing to the thymus9, 11. Myeloid APC populations can also be found in 
the cortex. Thymic macrophages are a heterogenous population found 
throughout the thymus and are thought to be the scavengers of apoptotic cells (of 
which there are many, as only about 3% to 7.5% of the pre-selection T cell 
repertoire becomes mature T cells)6, 12, 13, 14, 15, 16. Thymic eosinophils and 
neutrophils can also infiltrate the cortex and clear apoptotic cells, but it is not their 
only function: eosinophils, for example, interact with DP thymocytes at the 
cortico-medullary junction17, 18. While not as well-defined as the other 
hematopoietic APC, myeloid APC have also been implicated in thymocyte 
selection and activation17, 19. Cortical APC clearly mediate negative selection, as 
cortical deletion is a proportionally larger percentage of clonal deletion7, 20.  
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The thymic medulla is home to mTEC which play a crucial role in negative 
selection5, 9. These cells are specialized to express tissue restricted antigens 
(TRA), proteins normally produced only in one or two tissues in the body. An 
example of a TRA is insulin – a protein otherwise only produced in the pancreas. 
The thymic expression of TRA is essential to achieve self-tolerance to all proteins 
in the body. TRA expression in mTEC is largely dependent on a transcriptional 
regulator called autoimmune regulator protein (AIRE), but Fezf2, another 
transcription factor, may also promote TRA expression in an AIRE-independent 
fashion21.  
 
Thymic B cells also express AIRE and mediate negative selection9. These 
hematopoietic APC have an activated phenotype – higher levels of MHCII and 
costimulatory molecules compared to their splenic counterparts – and are found 
in the cortico-medullary junction and medulla. B cells are not the only 
hematopoietic APC in the thymic medulla; XCR1+ DC (also known as cDC1) and 
plasmacytoid DC (pDC) are also medullary. Like SIRPa+ DC, pDC are a 
migratory population that can transport peripheral antigens to the thymus and 
mediate negative selection22. XCR1+ DC are not migratory, but they also localize 
to the thymic medulla due to their interactions with their ligand, XCL1. XCL1 is 
produced by mTEChi in an AIRE-dependent fashion, and the XCL1-XCR1 
interaction allows accumulation of XCR1+ DC around mTEC23. These XCR1+ DC 
can then cross-present antigens acquired from mTEC, including TRA, and 
mediate negative selection.  
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1.4 Tolerance to temporally expressed antigens 
An effective immune system is one that can respond robustly to foreign 
pathogens without having unwanted responses against the host’s own cells and 
tissues. This immunological tolerance to self-antigens is enforced early during T 
cell development in thymus by negative selection. The phenomenon of 
ubiquitous and tissue restricted self-antigens being presented in the thymus is 
well-defined, but there are also self-antigens that are only expressed for a limited 
span of time. For these antigens with a temporal component, there also needs to 
be immunological tolerance. For example, pregnancy results in a semi-allogeneic 
fetus: there are non-self, paternal antigens, but also maternal (and therefore, 
self-) antigens. Pregnancy has a temporal component. In other words, women 
are not chronically pregnant. Indeed, Treg  are critical for immunological tolerance 
and successful gestation; and further, some Treg found in the decidua are of 
thymic origin24, 25. These reproduction-associated antigens are expressed in the 
thymus in an AIRE dependent fashion, and the loss of functional AIRE is 
associated with pregnancy loss and reduced fertility26, 27.  
 
Similarly, type I interferons (IFN-I) are cytokines that are rapidly produced during 
viral infections and lead to a wide breadth of immunological effects. These 
responses are characterized by the upregulation of various interferon stimulated 
genes (ISG)28. Even without infection, type I interferon is found at low levels in 
the thymus, and both thymocytes and thymic dendritic cells express ISG29, 30, 31. 
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Notably, during a viral infection, IFN-I production changes the self-peptide 
repertoire that is displayed by MHCI32. Given this, we hypothesize that thymic 
IFN-I impacts T cell tolerance. T cell tolerance could be enhanced through the 
presentation of interferon-induced self-peptides (an altered peptidome); but also 
by changes in thymic APC subsets, whether it be increased peptide presentation 
or overall changes in APC composition.  
 
1.5 Specialized lymphocytes 
Conventional ab and gd T cells are not the only cells that develop and emerge 
from the thymus. There are also specialized lymphocyte populations that are 
numerically fewer but still play important roles in host immune responses – 
helping maintain tissue and metabolic homeostasis. These include lipid-reactive 
natural killer T (NKT) cells, CD8aa+ intraepithelial lymphocytes (IEL), and 
mucosal-associated invariant T (MAIT) cells. Compared to conventional ab T 
cells, NKT cells and IEL express TCR that are more self-reactive10. Thus, their 
development is referred to as agonist selection in the thymus and these 
specialized lymphocytes require distinct molecular factors for their development.  
 
NKT cells express an ab TCR, but rather than being peptide specific and MHC 
class I or II restricted, they recognize lipid antigens in the context of CD1d 
molecules10, 33. The TCR repertoire expressed by NKT cells is highly restricted, 
consisting of either TCR Va14-Ja18 (mice) or Va24-Ja18 (humans) chains 
paired with limited TCR Vb chains. Due to this “invariant” TCR, these cells are 
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named invariant NKT (iNKT) cells. Selection of iNKT cells happens in the thymic 
cortex at the DP stage. However, rather than being positively selected by thymic 
cTEC like conventional T cells, iNKT cells are selected by other DP thymocytes 
presenting lipid antigens by CD1d, a non-classical MHCI-like molecule. Strong 
TCR signaling at this stage along with interactions between signaling lymphocyte 
activation molecule family (SLAMF) receptors drives agonist selection of iNKT 
cells. iNKT cells are specified by the expression of the transcription factor PZLF 
and can further differentiate into different iNKT effector subsets within the 
thymus. Like NKT cells, MAIT cells have a limited TCR repertoire due to 
restricted TCRa chain usage. These TCR generally consist of either Va19-Ja33 
(mice) or Va7.2-Ja33 (humans) paired with limited TCR Vb chains34. MAIT cells 
recognize metabolites of vitamin B in the context of the non-classical MHCI-like 
molecule MR1 and are selected for during the DP stage of thymocyte 
development by other DP thymocytes.  
 
IEL are T cells that reside within the gut epithelium and include a population that 
express ab TCR and CD8aa homodimers. These CD8aa+ IEL derive from 
agonist selected thymic precursors (IELp) and have a small repertoire size10, 35.  
During thymocyte selection, strongly self-reactive DP thymocytes undergo clonal 
deletion, but without CD28 co-stimulation, more cells are diverted into the IELp 
fate. These TCRab+ IELp can then be found within DN thymocyte population, 
and most are localized within the cortex in adult mice. This is a reflection of the 
two distinct IELp populations in the thymus: Type A IELp are PD-1+, self-reactive, 
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and largely cortical; while a more newly defined group, Type B IELp are PD-1-, 
non-self-reactive, and largely medullary36. In adults, Type A IELp are the 
proportionally larger population being exported from the thymus37. While it is 
known that these precursors are b2m-dependent, the relevant cortical APC 
needed for their development has not been identified. Given that more IELp 
developed in mice lacking CD28 co-stimulation, we hypothesize that this APC 
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2.1 Introduction  
Intraepithelial lymphocytes (IEL) are resident T cells located in the gut epithelium, 
where they protect against harmful pathogens, while also playing a regulatory 
role in preserving barrier homeostasis 38, 39. IEL are a heterogeneous population, 
broadly divided into conventional and unconventional subsets. Conventional IEL, 
otherwise known as induced IEL, are TCRab+CD4+ and TCRab+CD8ab+ cells 
generated from naïve T cells that have recognized foreign antigens in the 
periphery. Unconventional IEL, also known as natural IELs, include TCRgd+ T 
cells, and TCRab+ CD4–CD8a+CD8b– (CD8aa) T cells. Natural IEL derive from 
thymic precursors, but their developmental pathway(s) remain incompletely 
defined. In particular, we lack an understanding of the thymic antigen presenting 
cells that instruct their differentiation and trafficking. 
 
CD8αα IEL largely differentiate from thymic precursors that have received strong 
stimulation by self-antigens but escaped deletion, in a process termed agonist 
selection 39, 40, 41. Thymic precursors to CD8aa+ IEL (IELp) are found in the CD4–
CD8– double-negative (DN) population of the thymus and are TCRab+CD5+H-
2Kb+CD122+ 36, 42, 43, 44, 45. This precursor population is itself heterogeneous, with 
two major subsets that differ in both cell surface markers and T cell receptor 
(TCR) specificities 36, 45. The proportionally larger IELp population – Type A IELp 
– are a nascent population induced by strong TCR signaling, express PD-1, and 
readily emigrate from the thymus. The smaller population – Type B IELp – 
contribute little to the emigrating IELp pool in adult mice, and are PD-1–NK1.1+ 36. 
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Nonetheless, both IELp are capable of giving rise to CD8aa+ IEL in the gut, and 
recent evidence suggests Type B IELp make a larger contribution to the gut early 
in life, and become outcompeted by Type A IELp in adulthood 36, 37, 46. Most IELp 
are restricted to classical and non-classical MHC class I (MHCI) molecules 36, 43, 
44. Strong TCR engagement of MHCI together with CD28 co-stimulation results in 
death of thymic precursors (negative selection), and co-stimulation-deficient mice 
(either Cd28–/– or Cd80–/–Cd86–/–) had higher numbers of thymic IELp and 
intestinal CD8aa+ IEL 36, 47, 48. Thus, avoidance of clonal deletion, called ‘clonal 
diversion’, is thought to be a major driver of IELp development. However, little is 
known about the thymic antigen presenting cells (APC) that lead to this diversion 
36, 49. Given the above, we predict that such APC would express MHC class I and 
low or no CD80/86. 
 
While medullary thymic epithelial cells (mTEC) and thymic dendritic cells (DC) 
are known to drive clonal deletion in the thymus, they are not the only APC that 
mediate selection processes9. Here, we sought to determine the role of APC that 
support positive selection of IELp. Using bone marrow chimeras, we show that 
IELp require MHC class I on hematopoietic APC (hAPC). However, our data with 
selective depletion suggest that no single hAPC subset is responsible for IELp 
selection on its own. Moreover, CD80 co-stimulation alone can limit the Type A 
IELp fate, even without CD86. Collectively, our findings show that hAPC play a 
specialized role in clonal diversion, but specific thymic hAPC subsets may play 
functionally redundant roles. 
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2.2 Results 
2.2.1 Hematopoietic APC are required for IELp selection in the 
thymus  
Previous reports indicate that both CD8aa IEL in the gut and their thymic 
precursors of IEL are b2m-dependent, with 10 fold fewer signaled PD-1+ DN 
thymocytes in b2m deficient models36, 43, 44. However, there are many different 
thymic APC with b2m dependent MHC molecules expressed on the cell surface, 
including both hAPC (such as dendritic cells, B cells, macrophages, and 
eosinophils) and stromal APC (thymic epithelial cells) that can determine the fate 
of thymocyte selection9, 17, 50, 51. Therefore, we first sought to differentiate 
between the roles of hematopoietic and stromal APC for IELp development using 
bone marrow chimeras. WT or b2m-deficient marrow was used to reconstitute 
lethally irradiated b2m-deficient or WT recipients, respectively. Using congenic 
markers to differentiate host- and donor-derived IELp (Fig. 2.1A; typical IELp 
gating without congenic markers shown in Figure 2.2), we found that a 
significantly lower proportion of signaled DN thymocytes developed into mature 
(CD122+) IELp in mice with b2m-deficient marrow (Fig. 2.1B). This IELp 
reduction in these mice where b2m was deficient in hematopoietic cells was 
reflected in the reduction of both the PD-1+ Type A and NK1.1+ Type B IELp 
numbers (Fig. 2.1C). 
 
Our finding of significantly fewer IELp with b2m-deficient hAPC was recapitulated 
by a reduction in CD8aa+ IEL in the small intestine of these mice (Fig. 2.1D). 
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Taken together, our data suggest that MHC class I expression is required on 
hAPC to positively select developing Type A and Type B IELp, and these 
precursors may rely on a single or select hAPC for this activity. 
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Figure 2.1. Positive selection of IELp depends on MHC class I expressed on 
hematopoietic APC. (A) Representative flow cytometry plots of DN thymocytes 
in bone marrow chimeras (WT à WT shown). Full gating for IELp shown in Fig. 
2.2. Mature IELp were defined by CD122 expression alone due to the lack of H2-
Kb expression in mice with b2m deficient bone marrow. Donor and host cells 
were differentiated using congenic markers, CD45.1 and CD45.2. (B) Quantified 
percentage of donor-derived IELp after WT or B2m-/- bone marrow transfer into 
lethally irradiated recipients indicated. (C) Absolute number of PD-1+Type A IELp 
(left) and NK1.1+ Type B IELp (right) after WT or B2m-/- bone marrow transfer into 
lethally irradiated recipients indicated. (D) Absolute number of small intestine 
CD8aa IEL in the indicated bone marrow chimeras.  Each symbol in (B-D) 
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represents an individual mouse. Data are pooled from at least three independent 
experiments. Error bars show mean ± SD. *p£0.05, **p£0.01, ***p£0.001, ****p £ 








Figure 2.2. Gating for IELp. Representative flow cytometry gating strategy for 
type A and type B IELp. Signaled DN thymocytes identified by the expression of 
CD5 and TCRb, after excluding PBS57-CD1d tetramer+, CD25+, CD4+, and 
CD8+. Mature IELp were identified by CD122+H-2Kb+. Type A IELp identified as 
PD-1+ and type B as NK1.1+. Numbers adjacent to the outlined areas indicate the 
percentage of cells in each. 
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2.2.2 CD28 co-stimulation drives cells away from the Type A 
IELp fate 
Most T cell precursors that interact strongly via their TCR with self-peptide:MHC 
undergo apoptosis. However, some cells (including IELp) can escape deletion, 
and these high-affinity TCR interactions lead to other cell fates in a process 
termed “agonist selection”10, 49. These agonist-selected populations include T 
regulatory (Treg) cells, which require CD28 co-stimulation by CD80 and/or CD86 
for their development and function52, 53. In contrast, IELp are agonist-selected 
cells that are positively selected in the absence of CD28 co-stimulation36, 48. For 
the process of clonal deletion, the ligands for CD28 –CD80 (B7-1) and CD86 
(B7-2) – are not equivalently expressed, and several APC throughout the thymus 
express CD80 alone7. Given these patterns, we evaluated the role of 
costimulatory molecules in IELp development in CD86 knockout (KO) and 
CD80/CD86 double KO mice. Consistent with previous reports using CD28 mice, 
the number of Type A IELp increased in the CD80/86 double KO mice36, 48 (Fig. 
2.3A). Further, the double KO rescued IELp and CD8aa IEL numbers more 
effectively than CD86 deficiency alone, suggesting both CD80 and CD86 restrain 
the Type A IELp fate in the thymus(Fig. 2.3A, 2.3B). 
 
In agreement with our previous study indicating that Type B IELp are not rescued 
in CD28 deficient mice, numbers of thymic Type B IELp were not increased in 
CD80/86 double KO mice compared to WT and, in fact, trended in the opposite 
direction36 (Fig. 2.3A). Patterns for CD8aa IEL numbers followed Type A rather 
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than Type B IELp numbers in the double KO mice, which may be a reflection of 
the Type A IELp population being the proportionally larger IELp subset 
regardless of co-stimulation status (Fig. 2.3C). 
 
 
Figure 2.3. Co-stimulation by CD80 and CD86 restrains the Type A IELp 
fate. (A) Absolute cell number of type A IELp (left) and type B IELp (right) in WT, 
CD86 KO, and CD80/86 double KO mice.  (B) Absolute number of small intestine 
CD8aa IEL in WT, CD86 KO, and CD80/CD86 KO mice. (C) Representative data 
of expression of NK1.1 (Type B) and PD-1 (Type A) on CD122+ H2-Kb+ mature 
thymic IELp in WT, CD86 KO, and CD80/86 double KO mice. Each symbol in (A 
and B) represents an individual mouse. Data are pooled from 4 independent 
experiments. Error bars show mean ± SD. *p£0.05, **p£0.01, ***p£0.001, 
ANOVA with multiple comparisons.  
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2.2.3 Several subsets of hematopoietic APC express low levels 
of CD80 
Thymocyte selection is orchestrated by both hematopoietic and stromal derived 
APC, but these APC subsets express varying levels of co-stimulation, with CD80 
being more broadly expressed than CD86 overall7, 9. In light of our observation 
that hAPC were required for IELp selection and that CD80 co-stimulation 
restrained the Type A IELp fate, we hypothesized that the APC that selects Type 
A IELp is a hematopoietic cell that expresses MHCI but does not express CD80 
or CD86. While the majority of Type A IELp reside in the thymic cortex, some can 
be found in the medulla36. Therefore, we did a comprehensive examination of the 
various APC found in the thymus. We included not only the well-defined dendritic 
cell subsets – plasmacytoid DC (pDC) and the two conventional DC (cDC) 
populations defined by XCR1 (cDC1) or SIRPa (cDC2) – but also B cells and 
various myeloid cells, as they have all been implicated in thymocyte selection or 
activation9, 17, 19, 54, 55. Thymic myeloid populations have been described 
separately12, 17, 18, 56, so our APC gating strategy was designed to be 
comprehensive, and included several lineage markers such Siglec F 
(eosinophils) and Ly6G (neutrophils). As we found thymic F4/80+ cells are CD64+ 
(data not shown), CD64 was used to define thymic monocytes and macrophages 
after excluding eosinophils, which are F4/80+ as well (gating for thymic APC 
shown in Fig. 2.4). These myeloid populations, such as thymic eosinophils, are 
not trivial in the landscape of thymic APC, and are numerically some of the most 








Figure 2.4. Gating for thymic APC. Representative flow cytometry gating 
strategy for thymic hAPC. Top panels show gating for B cells and dendritic cells: 
pDC, XCR1+ cDC, and SIRPa+ cDC. Bottom panels show gating for myeloid 
populations: neutrophils, eosinophils, Ly6C- mononuclear phagocytes (MNP, 




Four populations became appealing candidates for the APC that select Type A 
IELp: pDC, B cells, Ly6C- mononuclear phagocytes (abbreviated Ly6C- MNP and 
include thymic macrophages), and neutrophils.  These four APC had low levels 
of CD80 and CD86 expression while expressing moderate to high levels of MHCI 
(Fig. 2.5B, 2.5C). Of these populations, Ly6C- MNP were of particular interest, as 
they were one of the most abundant APC found in the thymus (Fig. 2.5A), are of 
hematopoietic origin, and are localized both within the medulla and the cortex12, 
56. Conversely, the conventional DC populations expressed high levels of CD80 
and MHCI, suggesting that they may oppose self-reactive thymocytes becoming 
Type A IELp through deletion (Fig. 2.5B, 2.5C). Thus, to distinguish the role of 
the various APC subsets in Type A IELp selection, we employed different Cre-
recombinase transgenic strains bred to b2mfl/fl mice to specifically target MHCI 









Figure 2.5. Thymic APC have heterogeneous levels of MHC class I and 
CD80. (A) Absolute cell number of thymic APC. Each symbol represents an 
individual mouse; horizontal lines indicate the mean. Data are pooled from 3 
independent experiments. Representative expression of (B) CD80 and (C) H-
2Kb, a classical MHCI molecule on the indicated thymic APC populations. Note 
that all CD86 expressing APC in the thymus also express CD80 (7 and data not 
shown), thus CD80 negative APC also lack CD86. Graphs in purple indicate APC 





Table 2.1: Conditional deletion strategy. Where “-“ denotes no effect, “+” 
denotes significant effect, and “#” denotes mild effect in thymus 
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2.2.4 Conventional DCs drive cells away from the Type A IELp 
fate 
To determine the contribution of cDC to the Type A IELp fate, we crossed b2mfl/fl 
mice to zDC (Zbtb46) Cre to create mice that specifically targeted MHCI on 
SIRPa+ and XCR1+ DC (Figure 2.6A). In these zDC Cre-b2mfl/fl mice, we 
observed a higher proportion and number of Type A IELp (Figure 2.7), indicating 
that normally, thymocyte interactions with cDC skew cells away from the IELp 
fate. These data fall readily in line with previous work showing that thymic 
conventional DC contribute to negative selection of self-reactive thymocytes and 
















Figure 2.6. Tissue specific deletion of MHC class I using B2mfl/fl. (A) 
Representative expression of H2-Kb, a classical MHCI molecule, on thymic APC 
in Zbtb46Cre (zDCCre)-B2mfl/fl mice (blue) and B2mfl/fl littermate controls (black).  
(B) Representative expression of H2-Kb on thymic APC in ItgaxCre (CD11cCre)-
B2mfl/fl mice (orange), Lyz2Cre-B2mfl/fl mice (purple), Cd79aCre (Mb1Cre)-B2mfl/fl 











Figure 2.7. Conditional deletion of b2m in conventional DC drive more cells 
toward the Type A IELp fate. (A) Expression of NK1.1 (Type B IELp) and PD-1 
(Type A IELp) on CD122+ H2-Kb+ mature thymic IELp in Zbtb46Cre (zDCCre)-
B2mfl/fl and littermate control mice (left, representative data are shown). Numbers 
adjacent to the outlined areas indicate the percentage of cells in each. Quantified 
percentage of PD-1+ Type A IELp in zDCCre-B2mfl/fl and B2mfl/fl mice among 
signaled CD5+ TCRb+ DN thymocytes (right).  (B) Absolute number of Type A 
IELp in zDCCre-B2mfl/fl and B2mfl/fl mice. Each symbol in (A & B) represents an 
individual mouse. Data are pooled from 7 independent experiments. Error bars 
show mean ± SD. **p£0.01, unpaired two-tailed t test.  
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2.2.5 Hematopoietic APC have overlapping roles in selecting 
Type A IELp 
Although CD11c is a well-known marker for dendritic cells, CD11c (Itgax) Cre 
targets not only cDC, but also pDC and monocytes/macrophages58. Using CD11c 
Cre-b2mfl/fl mice confirmed that this targeting held true for thymic APC, with lack 
of MHCI on cDC, pDC, and MNP; and a partial reduction on thymic eosinophils 
and neutrophils (Fig. 2.6B). Intriguingly, while cDC in the thymi of CD11c Cre-
b2mfl/fl mice had robust MHCI loss, we did not see a replication of increased 
numbers of Type A IELp like in zDC Cre-b2mfl/fl thymi (Fig. 2.8A). Therefore, we 
reasoned that at least one of the other APC affected in the CD11c Cre-b2mfl/fl 
thymi might support Type A IELp selection. The absence of MHCI on this 
population could offset the increase in IELp numbers caused by fewer 
interactions with clonally deleting cDC, making interpretation of this result 
difficult.  
 
Thus, to distinguish the role of the myeloid APC subsets, we generated LysM 
(Lyz2) Cre-b2mfl/fl mice. In these mice, MHCI is targeted on thymic neutrophils, 
Ly6C+ inflammatory monocytes, and Ly6C- MNP, but not cDC (Fig. 2.6B). Both 
thymic neutrophils and Ly6C- MNP expressed low levels of CD80 on their cell 
surface, making them attractive candidates for the APC dedicated to Type A IELp 
selection (Fig. 2.5B). Nonetheless, the number of Type A IELp was not affected 
in LysM Cre-b2mfl/fl mice (Fig. 2.8B). As CD11c Cre perturbed MHCI expression 
on thymic pDC and eosinophils as well, we depleted these APC subsets 
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specifically. To assess the role of pDC on selection, pDC were ablated in BDCA2 
(Clec4c) DTR mice with diphtheria toxin (DT) administration every other day. 
After 9 days of DT treatment, there was no effect on Type A IELp numbers 
compared to BDCA2-DTR-/- littermate controls (Fig. 2.8C). Eosinophils were 
depleted using an aIL-5 antibody (clone TRFK5). After a 7-day course of aIL-5 
treatment, there was no effect on Type A IELp numbers compared to controls 
(Fig. 2.8D). Likewise, loss of MHCI on B cells in Mb1 (Cd79a) Cre-b2mfl/fl thymi 
(Fig. 2.6B), did not lead to Type A IELp reduction (Fig. 2.8E). 
 
Finally, we crossed the CD11c Cre-b2mfl/fl mice to Mb1 Cre to generate CD11c x 
Mb1 Cre-b2mfl/fl mice. These mice have MHCI depletion on a majority of hAPC. 
Thymi from these mice were not able to support normal levels of Type A IELp 
selection, as indicated by reduced numbers of Type A IELp compared to 
littermate controls (Fig. 2.8F). As single Cre models did not affect Type A IELp 
selection, while the dual Cre model (CD11c Cre x Mb1 Cre-b2mfl/fl) did, our data 




Figure 2.8. No single APC subset is dedicated to Type A IELp positive 
selection. (A) Absolute number of type A IELp in ItgaxCre (CD11cCre)-B2mfl/fl and 
littermate controls. Data are pooled from 4 independent experiments. (B) 
Absolute number of type A IELp in Lyz2Cre (LysMCre)-B2mfl/fl mice and littermate 
controls. Data are pooled from 3 independent experiments. (C) Absolute number 
of type A IELp in Clec4c (BDCA2)-DTR+/- mice and littermate controls after a 9d 
course of DT treatment. Data are pooled from 4 independent experiments. (D) 
Absolute number of type A IELp in WT mice treated with aIL-5 (clone TRFK5) or 
an IgG1 isotype control for 7d. Data are pooled from 3 independent experiments. 
(E) Absolute number of type A IELp in Cd79aCre (Mb1Cre)-B2mfl/fl and littermate 
controls. Data are pooled from 5 independent experiments (F) Representative 
data of expression of NK1.1 (Type B) and PD-1 (Type A) on CD122+ H2-Kb+ 
mature thymic IELp (left). Absolute number of type A IELp ItgaxCrexCd79aCre-
B2mfl/fl and littermate controls (right). Data are pooled from 3 independent 
experiments. For (A – F), the graph titles indicate the thymic APC populations 
affected in the experimental mice (Cre+, BDCA2 DTR+, aIL-5 treated). Each 
symbol represents an individual mouse. Error bars show mean ± SD. **p£0.01, 
unpaired two-tailed t test.  
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2.3 Discussion 
Type A IELp, the thymic precursors of CD8aa IEL in the gut, receive strong 
stimulation by self-antigens, yet escape clonal deletion36, 39, 40, 41. In this study, we 
investigated the thymic antigen presenting cells that orchestrate the decision of 
clonal diversion into IELp instead of deletion. Using b2m deficient bone marrow 
chimeras, we showed that MHCI expression on hAPC rather than stromal APC 
was crucial for selection of IELp. 
 
The current and previous studies have shown that CD28-mediated co-
stimulation, along with TCR stimulation, is important in determining thymocyte 
fate into the deletion pathway36, 47, 48. CD28 on developing thymocytes can 
interact with the ligands CD80 (B7-1) and CD86 (B7-2), but these two molecules 
are distinct – sharing only approximately 25% sequence identity, and are 
differentially expressed on various APC7, 59. We therefore hypothesized that the 
two B7 molecules serve non-redundant roles in selection. This was supported by 
our data in CD80/CD86 double knockout mice compared to the CD86 knockout 
mice. Out data support previous findings that CD80 serves a non-redundant role 
in mediating clonal deletion in the thymic cortex – the region in which most Type 
A IELp reside7, 36. These distinct roles may be due to differences in which APC 
express CD80 or CD86. Interestingly, hAPC in the thymus do not generally 
express CD86 alone, but rather express either CD80 alone or both CD80 and 
CD86.  Alternatively, these distinct roles may be due to differences in the 
interactions between these ligands and their mutual receptor, as CD86 is 
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predicted to bind more strongly to CD2860. Without the CD80/CD86 ligand 
interactions, CD28 accumulates only half as well at the immunological synapse 
and only needs CD86 expression for the CD28 accumulation, not CD8061.  
 
Given that our data showed that hAPC are required for Type A IELp selection 
and that CD28 co-stimulation restrains this fate, we examined the role of thymic 
APC that expressed MHCI with little/no CD80, or high levels of CD80. Similar to 
previous reports, we saw that thymic conventional DC expressed high levels of 
co-stimulatory molecules, which contributes to their role in deletional tolerance9, 
11. When we selectively depleted MHCI on cDC, so that class I restricted, self-
reactive developing thymocytes could no longer interact with these ‘deleting’ 
APC, we indeed found that more cells were diverted toward the Type A IELp fate. 
On the other hand, thymic pDC, Ly6C- MNP, B cells, and neutrophils expressed 
high levels of MHCI but minimal levels of CD80, suggesting a role in IELp 
positive selection. However, when we selectively depleted MHCI on each 
population individually, we did not see a decrease in Type A IELp selection as 
expected if that population was essential. Instead, we only found a decrease in 
Type A IELp when MHCI was depleted on the majority of hAPC, suggesting 
functional redundancy amongst CD80/86 neg/low APC in contributing to the 
diversion fate.  
 
Like thymic hAPC, DP thymocytes do not express CD80 or CD86, and it could be 
reasoned that they could potentially select IELp as well. Indeed, iNKT cells, 
 36 
another relatively self-reactive population, are selected on cortical DP 
thymocytes expressing lipid antigens on CD1d 33. However, DP thymocytes 
express very low levels of classical MHCI on their cell surface. Further, our 
results showed a decrease in IELp selection when classical MHCI was depleted 
on thymic APC alone. Thus, DP thymocytes, which represent the largest 
population of cells in the thymus, are an unlikely candidate for IELp selection. 
While CD1d itself is b2m dependent and was also likely depleted with classical 
MHCI in our cell-specific deletion of b2m, Type A IELp are not dependent on 
CD1d for selection36, 62.  
 
In conclusion, we showed that hAPC play an essential role in clonal diversion 
into the IELp fate, although it appears there is no single APC that is specialized 
for ‘diverting’ thymocytes to Type A IELp. In addition, the loss of co-stimulatory 
molecules on all APC exaggerates Type A IELp selection, while the presence of 




2.4 Materials and Methods 
2.4.1 Mice 
C57BL/6NCrl (B6) and B6.SJL-PtprcaPepcb/BoyCrl (B6.SJL) mice were 
purchased from the National Cancer Institute. B6.129P2-B2mtm1Unc/DcrJ (B2m-/-), 
B6.129S4-Cd80tm1Shr Cd86tm2Shr/J (CD80/CD86 KO), B6.Cg-Zbtb46tm3.1(cre)Mnz/J 
(Zbtb46Cre), B6.Cg-Tg(Itgax-cre)1-1Reiz/J (ItgaxCre), B6.C(Cg)-
Cd79atm1(cre)Reth/EhobJ (Cd79aCre), and C57BL/6-Tg(CLEC4C-HBEGF)956Cln/J 
(Clec4c DTR) mice were obtained from Jackson Laboratories. Cd80floxBACTg/ 
B6.129S4-Cd80tm1Shr Cd86tm2Shr/J, referred to as CD86 KO mice in this study, 
were kindly provided by R. J. Hodes (National Institutes of Health) and were 
described previously63. B6.B2mflox/flox (B2mfl/fl) mice were kindly provided by C. N. 
Morrell (University of Rochester School of Medicine) and were described 
previously64. B6.129P2-Lyz2tm1(cre)Ifo/J (Lyz2Cre) mice were kindly provided by M. 
Jenkins (University of Minnesota). Except the bone marrow chimeras, mice were 
used between 6 to 10 weeks of age, and were age-matched with controls in each 
experiment. Animal experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Minnesota. 
 
2.4.2 Bone marrow chimeras 
For bone marrow chimeras, recipients were depleted of NK cells with PK136, 
then lethally irradiated and reconstituted with donor bone marrow depleted of T 
cells. Chimeras were provided water supplemented with neomycin and polymyxin 
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B for 2 weeks. Chimeras involving B2m-/- recipients and bone marrow were 
analyzed at a minimum of 8 weeks after reconstitution.  
 
2.4.3 Lymphocyte isolation  
Single cell suspensions of thymocytes were isolated by mashing and filtering 
thymi through 70µM cell strainers (Falcon), or digestion with collagenase D 
(Roche, 1mg/mL) at 37°C for 30 minutes before mashing and filtering thymi 
through 70µM cell strainers. Small intestine IEL were isolated as previously 
described36 and filtered through 70µM cell strainers. Lymphocytes were enriched 
by centrifugation over a 80%:40% Percoll gradient. 
 
2.4.4 Flow cytometry 
Single cell suspensions were incubated with Fc block (Tonbo) for 15 minutes at 
4°C before staining with surface antibodies and viability dye for 30 minutes at 
37°C or 1 hour at room temperature. Antibodies from BioLegend were: CD4 
(RM4-5), CD8b (YTS156.7.7), CD25 (PC61), TCRgd (GL3), NK1.1 (PK136), 
CD45.2 (104), B220 (RA3-6B2), CD11c (N418), XCR1 (ZET), SIRPa (P84), 
CD90.2 (30-H12), CD19 (6D5), Ly6G (1A8), CD64 (X54-5/7.1), CX3CR1 
(SA011F11), and CD80 (16-10A1). Antibodies from BD Biosciences were: CD8α 
(53-6.7), TCRβ (H57-597), H2-Kb (AF6-88.5), Siglec F (E50-2440), and CD86 
(GL1). Antibodies from eBioscience were: CD5 (53-7.3), PD-1 (J43), CD122 (TM-
b1), F4/80 (BM8), MHC Class II (I-A/I-E, clone M5/114.15.2),  and Ly6C (HK1.4). 
CD11b (M1/70) was purchased from Tonbo. Biotinylated CD1d–PBS57 
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monomers were obtained from the US National Institutes of Health tetramer core 
and were incubated with APC streptavidin to tetramerize. Samples were acquired 
on a BD Fortessa or BD LSRII, and data were analyzed with FlowJo 10. 
 
2.4.5 APC subset depletion treatments 
For pDC depletion, Clec4c DTR and littermate controls were injected 
intraperitoneally (i.p.) with diphtheria toxin (DT; Sigma-Aldrich) in 100uL PBS 
every other day for 9 days (500ng DT for first injection, 100ng of DT for 
subsequent injections). For eosinophil depletion, B6 mice were treated i.p. every 
other day for 7 days with 25µg aIL-5 (TRFK5) or IgG1 isotype control (HRPN) in 
100uL PBS. Tissues for treated mice were harvested the day after the final 
injections.  
 
2.4.6 Statistical analysis 
Data were analyzed using GraphPad Prism software version 8.0. For comparison 
of two data sets, two-tailed, unpaired t tests were performed. For comparisons of 
three or more data sets, 1-way ANOVA with multiple comparisons was used for 
data analysis and calculation of p values. P values £ 0.05 were considered 
significant. Numbers of experimental replicates and additional details are 
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3.1 Introduction  
Type I interferons (IFN-I), which include IFNa and IFNb, are cytokines that are 
rapidly produced during viral infections and contribute to an effective anti-
microbial response65. IFN-I exposure leads to a wide breadth of immunological 
effects, mediated by various interferon stimulated genes (ISG). Not surprisingly, 
IFN-I is tightly regulated66. Type I interferon dysregulation has been associated 
with a number of autoimmune disorders, including systemic lupus 
erythematosus, rheumatoid arthritis, and multiple sclerosis, indicating a 
relationship between interferons and self-tolerance67, 68. Interferon production and 
signaling is not only found during infection, but also at low levels at the steady 
state69.  
 
Tonic levels of IFNb are particularly high in the thymus, where developing T cells 
undergo selection processes that remove self-reactive clones from the 
repertoire29. Correspondingly, developing T cells continually respond to thymic 
interferon30. In the absence of this signal, mature CD4 and CD8 single positive 
(SP) thymocytes fail to upregulate Qa2, a marker often used to define more 
mature SP thymocytes30, 70. Clonal deletion of self-reactive SP clones was initially 
thought to mostly occur at an earlier semi-mature stage, but more recent work in 
using a polyclonal repertoire indicates the deletion occurs in mature SP 
thymocytes as well7, 71.  
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SP thymocytes are generally found in the inner, medullary area of the thymus, 
where negative selection of auto-reactive cells is mediated by antigen presenting 
cells like medullary thymic epithelial cells (mTEC) and dendritic cells5. A subset 
of mTEC express autoimmune regulator (AIRE), driving expression of tissue-
restricted antigens (TRA) – a step critical for self-tolerance. Intriguingly, tonic 
IFNb is produced by mTEC in the thymus, rather than by plasmacytoid dendritic 
cells or other antigen presenting cells  (APC) that often produce IFN-I in 
response to viral pathogens29, 72, 73. The relationship between AIRE+ mTEC and 
IFNb remains controversial, however, making the role of thymic interferon on T 
cell tolerance difficult to define29, 72. Given this, we sought to better describe the 
expression of thymic IFNb and its effect on thymic antigen presenting cells. Using 
both IFNb reporter and knockout mice, we show that thymic IFNb is produced by 
a small subset of mTEC, and this expression is AIRE-dependent. We also report 
that both AIRE and IFNb have an age-dependent component to their expression, 
independent of overall thymic size – peaking early in life. Further, both 
thymocytes and thymic APC respond to IFNb, resulting in changes in thymic 
composition in the absence of tonic interferon signaling. Collectively, these 
findings provide valuable insight into the role of IFN-I on thymic APC, shedding 





3.2.1 Thymic interferon-b is produced by a subset of mTEChi 
cells at the steady state 
While IFNa consist of several isoforms encoded by 14 distinct genes, IFNb is 
encoded by a single gene66. To determine if developing thymocytes are capable 
to responding to IFNb specifically, we made use of both IFNb-deficient (Ifnb1-/-) 
and IFN-I receptor deficient (Ifnar1-/-) mice. Like previous reports that indicated 
that Qa2 upregulation was dependent on type I interferon signaling, we found 
lower levels of Qa2 in CD4SP thymocytes in both IFNb and receptor deficient 
mice, even in the absence of infection (Figure 3.1a, left panels). The decrease of 
Qa2 expression was similar between the Ifnb-/-  and Ifnar1-/- strains, suggesting 
that IFNb alone makes a large contribution to the type I interferon signaling in 
thymocytes. Besides type I interferons, there are other interferon families: type II 
and type III, all three of which signal through STAT174. STAT1 deficient (Stat1-/-) 
mice showed the deepest reduction in Qa2 levels, indicating interferon signaling 
through other pathways as well (Figure 3.1a, left panels). Like Qa2, Ly6A (Sca-1) 
is used to define mature thymocytes75, and Ly6A expression was also decreased 
in the absence of interferon signaling (Figure 3.1a, right panels). Like their 
CD4SP counterparts, CD8SP thymocytes showed interferon conditioning, with 














Figure 3.1. Developing T cells respond to IFNb. (a) Representative expression 
of Qa2 on CD4SP thymocytes from WT, Ifnar1-/-, Ifnb1-/-, and Stat1-/- mice (left). 
Qa2 geometric mean fluorescence intensity (gMFI) of CD4SP normalized to 
mean DP Qa2 gMFI (2nd panel). Representative expression of Ly6A on CD4SP 
thymocytes from WT, Ifnar1-/-, Ifnb-/-, and Stat1-/- mice (3rd panel). Ly6A gMFI of 
CD4SP normalized to mean DP Ly6A gMFI (4th panel). (b) Qa2 (left) and Ly6A 
(right) gMFI of CD8SP normalized to corresponding DP gMFI. Each symbol in (a 
& b) represents an individual mouse. Error bars show mean ± SD. *p£0.05, 
**p£0.01, ***p£0.001, ****p £ 0.0001, ANOVA with multiple comparisons.  
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Previous reports have suggested that thymic epithelial cells, particularly mTEC, 
produce IFNb29, 72. Using IFNb reporter mice in which IFNb has been replaced by 
firefly luciferase (Db-luc-mice29), we confirmed that CD45- thymic epithelial cells 
express higher levels of IFNb compared to their CD45+ counterparts (Figure 
3.2a). The highest levels of IFNb was seen in CD45- CD80+ cells, a population 
that encompasses the mTEChi subset – mTEChi express high levels of both 
MHCII and CD80, while cortical thymic epithelial cells (cTEC) and mTEClo do not 
express CD8076 (Figure 3.2a). This was also reflected in the highest levels of 
IFNb transcript in mTEChi sorted from wild-type mice (Figure 3.2b). Using a 
second reporter in which an IRES-tdTomato was knocked into the IFNb locus 
(IFNbKI/KI), we further found that only a very small subset of mTEChi are 
producing IFNb (Figure 3.2c). Taken together, our data suggest that the type I 
interferon signaling seen in developing thymocytes can be attributed to low 















Figure 3.2. IFNb is produced by mTEChi. (a) Luminescence of indicated cell 
populations (enriched using MACS bead enrichment) from thymi of Db-luc-mice. 
Each symbol represents an individual mouse. Data are pooled from 2 
independent experiments. Error bars show mean ± SD. **p£0.0, ANOVA with 
multiple comparisons. (b) Ifnb1 expression by qPCR in sorted cTEC, mTEClo, 
mTEChi, and total Liberase TH digested thymus (bulk) from wild-type B57BL/6 
mice (n=4) presented relative to that of sorted CD45+ cells from the same 
experiment. Error bars show mean ± SD. (c) Representative data of expression 
of IFNb-tdTomato in mTEChi from control (left) or reporter (right) strains.  
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3.2.2 Interferon-b is dependent on continuous AIRE expression 
While the majority of mTEC will express AIRE at some point during their 
differentiation, AIRE expression is restricted to a fraction of mTEChi at any given 
time77.  Of AIRE+ mTEC, only a subset will express any particular tissue-
restricted antigen, leading to expression of these antigens by very few mTEC – 
similar to the expression pattern of thymic IFNb5. Like with TRA, we found that 
IFNb expression was AIRE dependent, resulting in lower Ifnb transcripts in sorted 
mTEChi samples from AIRE deficient mice compared to WT controls (Figure 
3.3a). These data are in line with previous work using the Db-luc-mice on an 
AIRE deficient background29. Corresponding to the absence of IFNb produced by 
mTEC, developing CD4SP and CD8SP show a phenotypic lack of interferon 
conditioning in AIRE deficient mice (Figures 3.3b and 3.3c).  
 
For development of AIRE+ mTEC, RANK-RANKL signaling is critical78. Therefore, 
we treated mice with a single dose of blocking anti-RANKL antibody to determine 
if diminished AIRE expression would lead to reduced levels of IFNb. Only 48 
hours after the Db-luc-mice were treated, we saw significantly reduced 
expression of IFNb (Figure 3.3d). As expected, the RANKL blockade reduced 
AIRE+ mTEChi, without depleting AIRE- mTEChi, mTEClo, or cTEC (Figure 3.3e 
and data not shown). The decrease of AIRE+ mTEC in the RANKL treated mice 
could be due to the reduction of IFNb rather than the converse. However, when 
we looked at Ifnb1-/- and Ifnar-/- mice, we did not see a significant reduction in any 
thymic epithelial cell subset, indicating that differentiation is not dependent on 
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IFN-I signals (Figure 3.4), as previously suggested72. Rather, IFNb expression by 
mTEChi is dependent on continuous RANKL signaling and AIRE.  
 
 
Figure 3.3. IFNb expression is AIRE dependent. (a) Ifnb1 expression by qPCR 
in sorted mTEChi from WT and Aire-/- mice (n=2) presented relative to WT 
mTEChi. Error bars show mean ± SD. (b) Representative expression of Qa2 on 
CD4SP thymocytes from WT and Aire-/- mice; and Qa2 gMFI of CD4SP 
normalized to mean of DP Qa2 gMFI (top row). Representative expression of 
Ly6A on CD4SP thymocytes from WT and Aire-/- mice; and Ly6A gMFI of CD4SP 
normalized to mean of DP Ly6A gMFI (bottom row). (c) Qa2 (top) and Ly6A 
(bottom) gMFI of CD8SP normalized to corresponding DP gMFI. (d) 
Bioluminescence (as measured by average flux in photons/second) from in vivo 
imaging of Db-luc-mice injected with D-Luciferin (48 hours after treatment with a 
control or aRANKL antibody). Data are pooled from 4 independent experiments. 
(e) Representative data of expression of AIRE by flow cytometry in mTEChi from 
control IgG or aRANKL treated mice, 48h after treatment (left). Absolute cell 
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number of thymic AIRE+ mTEC (right). Data are pooled from 2 independent 
experiments. Each symbol in (b-e) represents an individual mouse. Error bars 









Figure 3.4. mTEC differentiation is not dependent on type I interferon. (a) 
Absolute number of TEC, cTEC, mTEC, mTEChi, and mTEClo in WT, Ifnar1-/-, and 
Ifnb1-/- mice. (b) Absolute number of AIRE+ mTEC in WT, Ifnar1-/-, and Ifnb1-/- 
mice. Data are pooled from 2 independent experiments. Each symbol in (a & b) 





3.2.3 Interferon-b production and AIRE expression peak early in 
life 
Immune responses change with age, characterized generally by declining 
immune function in the elderly79. There is increased susceptibility to viral 
infections in which production of interferons provides a protective effect, and, 
indeed, dendritic cells like plasmacytoid DC have an impaired capacity of type I 
interferon production in response to infection in aged individuals80. We reasoned 
that tonic IFN-I production in the thymus could also have an age component. By 
tracking the IFNb signal in the Db-luciferase reporter mice over time, we saw the 
highest levels of IFNb at approximately 3 weeks of age before dropping and 
plateauing by 8 weeks (Figure 3.5a). As thymic cellularity and composition is also 
known to have an age component81, 82, we tracked the number of mTEC with 
age. Overlapping with the IFNb expression in the thymus, the proportion of AIRE+ 
mTEC to all other thymic populations was highest at 3 weeks (Figure 3.5b). This 
was driven by the high overall numbers of AIRE+ mTEC in early life, as age-
related thymic involution does not occur until adulthood and thymic size is 
continues to increase after 3 weeks (Figure 3.6; data not shown for overall thymic 
cellularity). Thus, the age dependence of thymic interferon expression is likely 













Figure 3.5. Peak IFNb expression at 3 weeks of age corresponds to a peak 
in AIRE+ mTEC. (a) Representative in vivo images of Db-luc-mice injected with 
D-Luciferin at 2 weeks and 7 weeks of age (left). Bioluminescence (as measured 
by average flux in photons/second) from in vivo imaging of Db-luc-mice injected 
with D-Luciferin at different ages. Between 1 to 8 mice per time point; error bars 
show mean ± SD. (b) AIRE+ mTEC as a ratio to CD45+ cells (left axis, circles) or 
as a proportion of TEC (right axis, squares) in various ages of WT C57BL/6 mice. 
Data are pooled from 14 independent experiments, with at least 2 experiments 
















Figure 3.6. TEC numbers in Db-luc (IFNb reporter) and C57BL/6 mice. (a) 
Absolute number of AIRE+ mTEC in various ages of Db-luc-mice. Data are 
pooled from 2 independent experiments with n=2-3 per timepoint. Error bars 
show mean ± SEM. (b) Absolute number of mTEC (left axis, circles) or AIRE+ 
mTEC (right axis, squares) in various ages of WT C57BL/6 mice. Data are 
pooled from 14 independent experiments, with at least 2 experiments and 6 
individual mice per timepoint. Error bars show mean ± SEM. 
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3.2.4 Both thymocytes and thymic APC respond to type I 
interferons  
Although there are many subtypes of Type I interferons, they all share a 
heterodimeric receptor composed of 2 chains: IFN-a receptor 1 (IFNaR1) and 
IFN-a receptor 2 (IFNaR2). This receptor is expressed ubiquitously on all 
nucleated cells83.  Nonetheless, different cell types have distinct interferon 
responses: for example, in response to influenza, interferon responses – as 
measured by activation of Mx1, an interferon-stimulated gene – are contained 
mostly within the  hematopoietic compartment and is especially high within Ly6C+ 
monocytes84. In the thymus, the hematopoietic APC compartment includes 
dendritic cells, B cells, and various myeloid populations, many of which have 
been implicated in thymocyte selection or activation9, 17, 19, 54, 55. Using Mx1GFP 
reporter mice, we observed tonic interferon signaling in the majority of cells in the 
thymus, with the exception of neutrophils and eosinophils (Figure 3.7a; gating 
shown Figure 2.4). When these Mx1GFP reporters were bred onto to an Ifnar1-/- 
background, we saw reduced levels of GFP, indicating that these cells normally 
respond to type I interferon (Figure 3.7a and 3.7b). When crossed to a Stat1-/- 
background, these reductions were deeper and broader, suggesting that IFN-II or 
-III signaling may shape the APC compartment as well, particularly for B cells 
and XCR1+ DC (Figure 3.7a and 3.7c). Without type I interferon signaling in the 
thymus, there were significant reductions in the number of hematopoietic APC, 
particularly in pDC and Ly6C+ monocytes (Figure 3.8). Again, these changes to 
APC were deeper and broader when all interferon signaling was abolished in 
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Stat1-/- mice, suggesting that non-IFN-I signaling also shapes the APC 







Figure 3.7. Most cells in the thymic environment respond to type I 
interferons at the steady state. (a) Quantified percentage of GFP+ cells of 
various thymic populations in Mx1GFP reporter mice on wildtype, Ifnar1-/-, or Stat1-
/- backgrounds. (b) Representative data of expression of Mx1GFP in various 
hematopoietic APC from control wildtype C57BL/6; Mx1GFP-Ifnar1+/+, and 
Mx1GFP-Ifnar-/- mice. Only APC with the largest change between the Ifnar1+/+ 
and Ifnar-/- strains are shown. (c) Representative data of expression of Mx1GFP in 
various hematopoietic APC from Mx1GFP-Stat+/+, and Mx1GFP-Stat-/- mice. Only 
APC with the largest change between the Stat+/+ and Stat-/- strains are shown. 

















Figure 3.8. Thymic interferon changes hematopoietic APC composition. 
Absolute number of various hematopoietic APC in WT, Ifnar1-/-, and Stat1-/- mice. 
Data are pooled from 2 independent experiments. Each symbol represents an 




Type I interferons are typically thought of in the context of viral infections, but 
more recently, their constitutive expression has been noted at low levels in some 
organs like the thymus29, 65, 72, 84. In this study, we examined the source of thymic 
IFNb and its effect on thymic APC. Using both IFNb reporters and subset 
enrichments, we showed that mTEChi produce IFNb at the steady state in an 
AIRE dependent fashion. A transcriptional regulator, AIRE allows mTEChi  to 
induce expression of various tissue restricted antigens – a role that is critical for 
negative selection in thymus5. The ability of AIRE to promote promiscuous gene 
expression is mediated by its various molecular partners, many of which are still 
elusive85. Similar to the expression of TRA by AIRE+ mTEChi, we found that only 
a small subset of mTEChi expressed IFNb, rather than continuous expression by 
all cells. 
 
The importance of AIRE expression is seen in mice and humans that have Aire 
mutations: both have autoantibody production and multi-organ autoimmune 
manifestations86, 87, 88. In humans, mutations in Aire lead to autoimmune 
diseases, particularly in endocrine organs, and is referred to as autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy (APECED) or autoimmune 
polyendocrine syndrome 1 (APS-1). Intriguingly, antibodies against type I 
interferons, both IFNa and IFNb, can be found in APS-1 patients89.  
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During viral infections, the response by APC to IFN-I includes the upregulation of 
MHC and costimulatory molecules on their cell surface, which promotes robust T 
cell responses90. Similarly, type I interferon signaling in thymic APC may promote 
antigen presentation by driving expression of related genes, thereby mediating 
thymic selection processes. As well as thymic IFN-I, there is also tonic type III 
interferon (IFNl) expression by mTEC91. This thymic IFNl enhances MHC class I 
molecules on both cTEC and mTEC, and Ifnlr1-/- mice are characterized by both 
aberrant thymic selection and autoantibody production91. Thymic interferons do 
not only affect antigen presentation on individual antigen presenting cells, but 
also affects selection by changing the APC compartment as a whole. Here, we 
found that both Ifnar1-/- and Stat1-/- mice had significantly fewer hematopoietic 
thymic APC, the latter of which included conventional DC and B cells – both 
known to play a role in negative selection9.  
  
The dependence of IFNb expression on AIRE was shown not only by our data of 
lower  levels in Aire-/- and aRANKL-treated mice, but was also reflected by the 
overlapping dynamics of AIRE and IFNb expression in early life. We found that 
the ratio of AIRE+ mTEC to other thymic populations changes rapidly in early life, 
with the highest proportion of AIRE+ mTEC occurring at around 3 weeks of age. 
This ratio and, in a 3-D sense, the larger physical network of mTEC in the thymic 
medulla likely informs thymocyte development: an increased AIRE+ mTEC to 
thymocyte ratio allows for increased physical interactions between the two 
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populations. The IFNb production by mTEC, then, exposes a higher proportion of 
thymic cells, both thymocytes and other APC, to IFN-I.  
 
In summary, we showed that tonic IFNb is produced by thymic mTEChi in an 
AIRE dependent fashion. Both AIRE and IFNb expression peak at around 3 
weeks of age, before dropping swiftly and plateauing. In addition, most thymic 






3.4 Materials and Methods  
3.4.1 Mice 
C57BL/6NCrl (C57BL/6) were purchased from the National Cancer Institute. 
B6.129S2-Ifnar1tm1Agt/Mmjax (Ifnar1-/-), B6.129S(Cg)-Stat1tm1Dlv/J (Stat1-/-), and 
B6.129S2-Airetm1.1Doi/J (Aire-/-) were obtained from Jackson Laboratories. 
B6.129P2-Ifnb1tm1Acgp mice (Ifnb1-/-) were kindly provided by E. Fish and have 
been described previously92. IFNbtdTomato (IFNbKI/KI) were kindly provided by D. B. 
Stetson (University of Washington). B6.Cg-Mx1tm1.1Agsa/J (Mx1GFP) were kindly 
provided by A. García-Sastre (Icahn School of Medicine at Mount Sinai) and 
have been described previously84. IFN-β+/Δβ-luc (Db-luc) were kindly provided by S. 
David (University of Minnesota) and have been described previously29. Unless 
noted, mice were used at approximately 5 weeks of age. For AIRE depletion, 
mice were injected i.p. with a single dose of 100µg of anti-RANKL (BioXCell; 
clone IK22/5) or isotype control (BioXCell; 2A3). Animal experiments were 
approved by the Institutional Animal Care and Use Committee of the University of 
Minnesota. 
 
3.4.2 Cell isolation 
Single cell suspensions of thymocytes were isolated by mashing and filtering 
thymi through 70µM cell strainers (Falcon), or digestion with collagenase D 
(Roche, 1mg/mL) at 37°C for 30 minutes before mashing and filtering thymi 
through 70µM cell strainers for T cell and CD45+ thymic APC. Thymic epithelial 
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cells were isolated using Liberase TH (Roche) digestion as previously 
described93. TECs were enriched by panning (also described93) prior to cell 
sorting, but not for direct flow cytometric analysis. Cells were sorted on a 
FACSAria (Becton Dickinson) and populations were reliably >90% of the target 
population.  
 
3.4.3 Flow cytometry 
Single cell suspensions were incubated with Fc block (Tonbo) for 15 minutes at 
4°C before staining with surface antibodies and viability dye for 30 minutes at 
4°C or 1 hour at room temperature. For AIRE staining, cells were 
fixed/permeabilized using the FoxP3/transcription factor staining buffer set from 
either eBioscience or Tonbo following the manufacturer’s protocol. AIRE staining 
was done at 30 minutes at room temperature. Antibodies from BioLegend were: 
CD4 (RM4-5), CD11c (N418), CD19 (6D5), CD25 (PC61), CD45 (30-F11), 
CD45.2 (104), B220 (RA3-6B2), CD64 (X54-5/7.1), CD80 (16-10A1), CD90.2 
(30-H12), CX3CR1 (SA011F11), F4/80 (BM8), I-Ab (AF6-120.1), Ly-51 (6C3), 
Ly6A/E (D7), Ly6G (1A8), SIRPa (P84), and XCR1 (ZET). Antibodies from BD 
Biosciences were: CD4 (GK1.5), CD8α (53-6.7), CD69 (H1.2F3), Siglec F (E50-
2440), and TCRβ (H57-597). Antibodies from eBioscience were: AIRE (5H12) , 
EpCAM (G8.8), F4/80 (BM8), Ly6C (HK1.4), and MHC Class II (I-A/I-E, clone 
M5/114.15.2). CD11b (M1/70) was purchased from Tonbo. FoxP3 (FJK-16s) was 
purchased from Thermo Fisher. UEA-I was purchased from Vector Laboratories.  
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Samples were acquired on a BD LSRFortessa, and data were analyzed with 
FlowJo 10. 
 
3.4.4 Luciferase assays 
For ex vivo luciferase measurement of populations from Db-luc-mice, MACS 
separation columns were used (Miltenyi Biotech): depletion with CD45 
microbeads was followed by CD80 enrichment (labeling with PE conjugated 
CD80, anti-PE microbeads). Samples were treated with cell culture lysis buffer 
(Promega), and luciferase activity was measured in a luminometer (Berthold) 
using the luciferase assay system following the manufacturer’s protocol 
(Promega).  
 
For in vivo imaging, mice were injected i.p. with D-luciferin in PBS (Goldbio), 
anesthetized using Isoflurane (Piramal) and analyzed using a Xenogen IVIS 100 
imaging system (Caliper, a PerkinElmer company). Photon flux was quantified 
using Living Image (Caliper). 
 
3.4.5 Quantitative RT-PCR (qPCR) 
RNA from sorted cells was extracted using an RNeasy mini kit (Qiagen). cDNA 
was produced using SuperScript III First Strand Synthesis SuperMix (Invitrogen). 
FastStart Universal SYBR Green Master (Roche) and an ABI PRISM 7900HT 
sequence detection system (Applied Bioscience) were used for amplification and 
detection. Gapdh was used for normalization of samples. Primers for Ifnb1 were 
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forward: CCC TAT GGA GAT GAC GGA GA, reverse: CTG TCT GCT GGT GGA 
GTT CA. 
 
3.4.6 Statistical analysis  
Data were analyzed using GraphPad Prism software version 8.0. For comparison 
of two data sets, two-tailed, unpaired t tests were performed. For comparisons of 
three or more data sets, 1-way ANOVA with multiple comparisons was used for 
data analysis and calculation of p values. P values £ 0.05 were considered 
significant. Numbers of experimental replicates and additional details are 
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The development of a functional but self-tolerant T cell repertoire is dependent 
on selection processes that happen in the thymus5. Selection is mediated by 
thymic antigen presenting cells, as the T cell receptors on the developing 
thymocytes engage with self-peptide:MHC presented by APC. Negative selection 
removes strongly self-reactive T cells from the conventional T cell repertoire. The 
APC that provide the signals that determine thymocyte fate are found throughout 
the thymus, and each subset has distinct localization and surface molecule 
expression9. The aim of this body of work was to gain a better understanding of 
how these thymic APC coordinate selection, particularly the selection of IELp and 
the production of type I interferon in the thymus. 
 
To better understand selection of IELp, we made use of bone marrow chimeras 
with WT and b2m deficient bone marrow. We found that hematopoietic APC were 
required for IELp selection, rather than radio-resistant stromal cells like cTEC 
and mTEC. Further, CD80 and CD86 co-stimulation restrained the Type A IELp 
fate, so we hypothesized that the selecting APC would be MHCI+ but lack 
expression of CD80/CD86. While we found several subsets of thymic APC with 
those characteristics, selective depletion of MHCI on individual APC subsets or 
depletion of the subset itself did not lead to decreased IELp selection. Rather, 
there was functional redundancy amongst the hematopoietic APC, and only 
broad defects in MHCI expression led to fewer Type A IELp. Specifically, we did 
not see an effect in Type A IELp numbers in CD11c Cre-b2mfl/fl or Mb1 Cre-
b2mfl/fl, but did see a significant reduction of precursors in CD11c Cre x Mb1 Cre-
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b2mfl/fl mice. In some ways, this was relatively surprising, as it indicated that 
MHCI expression on B cells was capable of supporting Type A IELp selection in 
the CD11c Cre-b2mfl/fl strain. B cells, while relatively low in CD80/CD86 
expression compared to cDC, are found in the thymic medulla and cortico-
medullary junction9. Type A IELp, however, are generally cortical and are found 
throughout the cortex – not just clustered around the border36. This suggests that 
Type A IELp may go through the thymic medulla (or at least the cortico-medullary 
junction) during development, but receive signals that attract them back into the 
thymic cortex before emigrating from the thymus. Unlike Type A IELp, Type B 
IELp are generally medullary, but there is no immediate relationship between the 
two populations as precursor-product during development36. Rather, Type A and 
Type B are likely to be parallel developmental pathways. It is still unclear, 
however,  if the APC that select for Type A IELp have other defining 
characteristics that make them ‘diverting’ APC other than the lack of 
costimulatory molecules. Further, while there is currently no tool to distinguish 
CD8aa+ IEL that derive from Type A or Type B IELp, due to the differences in the 
precursor populations, it seems likely that they play different roles at the gut 
barrier surface.  
 
To better understand the role of tonic type I interferon in the thymus, we first 
sought to determine the cellular source. Aligning with previous work, we found 
that mTEChi produced IFN-I at the steady state29, 72. Like the name suggests, 
mTEChi express high levels of costimulatory molecules and MHC class II76, 
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positioning the thymic interferon in the environmental context of interactions that 
can lead to negative selection of thymocytes. Further, like the expression of 
tissue restricted antigens, IFNb production in the thymus was dependent on 
AIRE86. This stringent dependence on AIRE for IFNb production was also 
reflected by the dynamic peak of both early in life. This peak occurred at around 
3 weeks of age and was followed by a prompt decline; intriguingly, this was 
independent of overall thymic size, as thymic cellularity does not follow this rapid 
timeline. While it has been previously appreciated that TEC populations are 
particularly dynamic during early life82, this is the first time that AIRE+ mTEC have 
been followed specifically. Using a RANKL blockade, we also showed that IFNb 
expression was sensitive to RANK-RANKL signaling in the thymus, through its 
effects on AIRE+ mTEC. The need for RANK-RANKL signaling for the 
differentiation of AIRE+ mTEC is well-described78, and there is interest in 
repurposing RANKL blockade for cancer immunotherapy. RANKL blockade 
(denosumab) is currently used for bone and breast cancer due to its role in 
osteoclastogenesis and mammary stem cell expansion94. However, the 
reasoning behind the repurposing of RANKL blockade for other cancer types is 
due to its effects on AIRE+ mTEC: the depletion of AIRE+ mTEC will likely lead to 
production of more anti-tumor T cells95. Our work suggests that an 
immunotherapy that targets AIRE+ mTEC would be most effective early in life, 
perhaps in pediatric cancer. It is possible, however, that the dynamics of the 
stromal compartment in mice does not represent the human thymus, and more 
work will need to be done.  
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As for the role of thymic IFN-I in tolerance, we found that most cells in the thymus 
respond to IFN-I, including antigen presenting cells and thymocytes. While 
producing IFNb, mTEChi responded only weakly to type I interferon at the steady 
state. Other APC populations such as pDC, SIRPa+ DC, and Ly6C+ monocytes 
responded robustly, indicating that there are distinct interferon responses by 
APC. Further, these responses were both deeper and broader in Stat1-/- mice, 
indicating that other interferons, such as type II and type III, may play a role in 
shaping the APC compartment as well. Here, we have shown that thymic 
interferon changes the hematopoietic APC in terms of number. This can affect T 
cell tolerance by altering the likelihood of a specific of interaction between a 
developing thymocytes and an APC subset. For example, a thymocyte that would 
have undergone clonal deletion after a strong interaction with an self-
peptide:MHC on an XCR1+ DC no longer has that interaction due to fewer XCR1+ 
DC in Stat1-deficient mice.  
 
Thymic interferon may not only affect the quantity of interactions, but the quality 
of those interactions as well. During viral infections, dendritic cells respond to 
type I interferon by upregulating MHC and costimulatory molecules on their cell 
surface96. Although not explored here, it seems likely that the response to thymic 
interferon is similar, causing the upregulation of genes affecting antigen 
processing and presentation by APC subsets. Further, thymic interferon could 
affect not only how peptides are presented, but what peptides are presented. In 
support of this, others have shown that during a viral infection, the peptidome 
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expressed on MHCI does indeed change32. The qualitative impact of tonic 
interferon on thymic APC and the resulting changes in the T cell repertoire will be 
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